Ranfac Corp.

What Ranfac Corp. does

Ranfac Corporation is a privately held, family-owned medical device manufacturer founded in 1888 and headquartered at a 40,000 sq. ft. vertically integrated facility in Avon, Massachusetts. The company operates a single-source contract development and manufacturing platform for hypodermic-based Class I and II medical devices, covering metal machining (12 processes including Swiss-type CNC, laser and TIG welding, electropolishing, swaging, and ultrasonic cleaning), polymer insert and overmolding in a Class 8 cleanroom, Class 7 cleanroom assembly with ERP-tracked barcode traceability, and pre-validated ethylene oxide sterilization through an exclusive partnership with STERIS. Ranfac serves medical device OEMs across CDMO engagements (concept-to-cleared, including DFM and 510(k) / EU MDR technical-file support), CMO engagements (cleared-to-scaled), and proprietary OEM product sales.

The company's proprietary product portfolio is anchored by the patented SNARECOIL™ bone marrow biopsy needle family (8G-13G gauges, 2"-6" lengths with a captive specimen-capture mechanism), an RTN bone marrow biopsy variant, a General Surgery line including the IN-12 insufflation needle (FDA K930474), LAP-13 and XL-11 cholangiography catheters, RSG-14 puncture closure device, KPL-4 knot pusher ligator, and PIN-15 percutaneous introducer needle. In October 2023, Ranfac completed its first acquisition in 135 years by acquiring Cervos Medical, LLC., a developer of autologous tissue processing technologies for orthobiologic applications, which operates as a wholly owned subsidiary.

Ranfac generates revenue through multi-year CDMO/CMO contracts negotiated per project scope, volume, and regulatory complexity, plus unit-based pricing on proprietary OEM products. Customer acquisition runs on enterprise field sales with senior leadership direct engagement and industry referrals; named customers include Health Beacons (acquired by Hologic), ProAct (20+ year supplier relationship), BONESUPPORT, Zimmer Knee Creations, Integra, Anika Therapeutics, Hologic, and Varian. The firm holds ISO 13485:2016, MDSAP, EU MDR CE Mark, and FDA 21 CFR 820 registration, granting regulatory access to seven major markets (US, EU, UK, Canada, Japan, Australia, Brazil) from the single Avon facility.

Name

Ranfac Corp.

Legal name

Ranfac Corporation

Website

https://ranfac.com

Company type

Private

Founded year

1888

Operating status

Operating

Headcount range

51–100 employees

Short description

Ranfac Corporation, founded 1888 and family-owned, is a single-source CDMO/CMO for hypodermic-based Class I and II medical devices, operating a vertically integrated 40,000 sq. ft. facility in Avon, MA serving medical device OEMs worldwide.

Ownership category

akta.pro rank

Product category

Medical Device Contract Manufacturing

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industry

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Medical device manufacturing
• Hypodermic needle manufacturing
• Contract medical manufacturing
• Bone marrow biopsy needles
• Sterile medical packaging

Headquarters

HQ city

Maussane

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. CDMO Services: Full development cycle services for concept-to-clearance: DFM, process validation, regulatory submissions (510(k) support, EU MDR technical files), and scaled production under customer brand with complete design history file management.
2. CMO/Manufacturing Services: High-volume, validated manufacturing for cleared device designs. Customers integrate into existing quality system or extend Ranfac's. Full traceability and real-time ERP visibility.
3. OEM Product Sales: Proprietary portfolio of single-use hypodermic-based medical devices including SNARECOIL™ bone marrow biopsy needles, surgical instruments, and hematology products. Available for direct purchase or distribution.
4. Cervos Medical (Subsidiary): Wholly owned subsidiary acquired October 2023. Develops autologous tissue processing technologies for orthobiologic applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Ranfac Corp. is a vertically integrated contract manufacturer (CDMO/CMO) of custom hypodermic-based medical devices, producing Class I and II sterile finished devices from raw metal and polymer under a single roof in Avon, MA. The company combines 12 precision metal machining processes, Class 8 cleanroom polymer molding, Class 7 cleanroom assembly, and pre-validated EO sterilization through STERIS into one continuous production system with a single quality system and one design history file. Ranfac also sells its own proprietary portfolio of minimally invasive devices, including the SNARECOIL™ bone marrow biopsy needle family and general surgery instruments.

Product overview

Ranfac Corp. is a vertically integrated medical device manufacturer offering custom hypodermic-based devices from raw material to sterile finished goods. The company operates a 40,000 sq. ft. single-facility in Avon, MA with capabilities spanning metal machining, polymer molding, cleanroom assembly, and EO sterilization. The proprietary product portfolio includes the SNARECOIL™ family of bone marrow biopsy needles (8G–13G, 2"–6" configurations) and a General Surgery product line (cholangiography catheters LAP-13 and XL-11, insufflation needle IN-12, puncture closure device RSG-14, knot pusher ligator KPL-4, and percutaneous introducer needle PIN-15). The company also offers CDMO and CMO contract manufacturing services. In October 2023, Ranfac acquired Cervos Medical LLC., a developer of autologous tissue processing technologies, operating as a wholly owned subsidiary. The manufacturing platform supports Class I and II devices with low minimum order quantities, scaling from first production runs to 500K+ units per year.

Differentiator

Problem solved

Functional benefit

Brands

• SNARECOIL™: Patented bone marrow biopsy needle product line featuring captive specimen-capture mechanism for long, non-fragmented core recovery. Available in 8G to 13G gauges and 2" to 6" lengths.

Products and services

• SNARECOIL™ Bone Marrow Biopsy Needle
• Knot Pusher Ligator (KPL-4)
• Percutaneous Introducer Needle (PIN-15)
• Puncture Closure Device (RSG-14)
• LAP-13 Cholangiography Catheter (Port Access)
• XL-11 Cholangiography Catheter (Percutaneous Access)
• IN-12 Insufflation Needle
• CDMO Services (Concept to Cleared)
• CMO Services (Cleared to Scaled)
• Cervos Medical (Wholly Owned Subsidiary)

Quantifiable outcome

• Manufacturing timeline accelerated 3-6 months through pre-validated STERIS sterilization partnership
• +2 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Cervos Medical, LLCcoreStrategic or Co-development Partner · 2 October 2023Wholly owned subsidiary acquired October 2023 as Ranfac's first acquisition in its 135-year history. Cervos Medical specializes in autologous tissue harvesting and processing technologies for the orthobiologic industry. Operates independently under Ranfac ownership, leveraging Ranfac's resources to expand product development and market reach.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vygon: French-headquartered single-use medical device manufacturer specializing in IV access, neonatology, and surgical devices. Comparable vertically integrated single-use device business model with similar product categories, though focused on European clinical markets.
• Argon Medical Devices: Specialty medical device manufacturer focused on biopsy, drainage, and vascular access products. Comparable in scale and product mix to Ranfac's hematology and MIS access categories, with a similar mid-size OEM/private-equity-backed operating model.
• Tegra Medical: Medical device contract manufacturer specializing in precision metal and plastic components, surgical instruments, and finished device assembly. Highly comparable to Ranfac's metal machining plus molding integration, serving orthopedics, surgical, and interventional OEMs.
• Nordson Medical: Medical device component and contract manufacturing division of Nordson Corporation. Offers precision tubing, needles, and OEM device manufacturing directly comparable to Ranfac's metal machining and hypodermic capabilities.
• SMC Ltd. Privately held medical device contract manufacturer offering plastic molding, assembly, and sterile packaging. Comparable high-mix, low-to-mid volume CDMO model serving OEMs from concept through production, though without the in-house metal machining depth Ranfac offers.
• Integer Holdings: Pure-play medical device contract manufacturer offering design, manufacturing, and supply chain services for cardio, vascular, and surgical devices. Most directly comparable CDMO business model to Ranfac, though at significantly larger scale across multiple global facilities.

Broad incumbents

• ICU Medical: Major manufacturer of IV catheters, needle-free connectors, and safety hypodermic devices following its acquisition of Smiths Medical. Competes with Ranfac's hypodermic-based device portfolio, particularly in safety needles and infusion access.
• Becton Dickinson (BD): Largest global hypodermic needle and injection device manufacturer. BD's hypodermic, biopsy, and surgical product lines directly overlap with Ranfac's SNARECOIL portfolio; BD's Medical segment also operates a CDMO-style OEM services business.
• Teleflex: Global medical device manufacturer with a large hypodermic, biopsy, and surgical access portfolio. Overlaps with Ranfac's SNARECOIL biopsy needle and MIS access product categories, but operates at vastly larger scale across broader clinical segments.

Others

• STERIS (as adjacent enabler): Ranfac's exclusive EO sterilization partner. Not a competitor but a critical ecosystem enabler; STERIS's contract sterilization business and validation infrastructure is integral to Ranfac's pre-validated sterilization value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ranfaccorp
• LinkedInlinkedin.com/company/ranfac-corp
• Instagraminstagram.com/ranfac1888
• Xx.com/Ranfac

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ranfac Corp.